United Therapeutics CEO executes and sells options under pre-arranged 10b5-1 plan
Rhea-AI Filing Summary
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics (UTHR), reported option exercises and stock sales executed under a pre-arranged 10b5-1 plan. On 09/19/2025 and 09/22/2025 she exercised stock options with an exercise price of $120.26, acquiring 4,000 shares on each date and immediately selling the same or part of those shares in multiple trades at weighted-average prices reported as $411.0775, $416.7188 and $417.8875. The filing shows direct beneficial ownership of 4,130 shares and indirect holdings through spouse and family trusts totaling reported blocks of 166, 324,518, 258,117, 45,596 and 15,962 shares. The transactions were carried out pursuant to a 10b5-1 plan established May 2, 2025, which continues until tranche exhaustion (294,000 options expiring 03/15/2026) or December 31, 2025.
Positive
- Transactions executed under a disclosed 10b5-1 trading plan, which provides pre-arranged, documented trading intent
- Detailed disclosure of indirect holdings via spouse and family trusts (specific share counts are reported)
- Weighted-average sale prices provided for multi-trade executions and offer to provide full trade-level details upon request
Negative
- None.
Insights
TL;DR: Routine insider option exercises and sales under a disclosed 10b5-1 plan; no new compensation grants or unexplained transfers reported.
The Form 4 documents exercises of stock options at a specified $120.26 exercise price followed by contemporaneous sales executed in multiple trades with weighted-average proceeds reported. The transactions are explicitly tied to a pre-arranged 10b5-1 trading plan dated May 2, 2025, which mitigates concerns about selective trading timing. The filing lists both direct and substantial indirect holdings via family trusts and spouse, providing a clear picture of aggregate beneficial ownership. There are no indications in the filing of additional compensatory awards, pledges, or material changes to long-term option positions beyond the disclosed tranche and expiration date.
TL;DR: Disclosure appears complete for these transactions; use of a documented 10b5-1 plan supports governance transparency.
The reporting person checked the box indicating transactions were pursuant to a 10b5-1 plan and supplied explanatory notes including tranche size and plan termination conditions. The filing discloses indirect holdings through multiple family trusts and spouse, clarifying potential indirect influence. Signature and power-of-attorney information are provided. Based solely on the Form 4 content, this is a routine, well-documented insider transaction rather than a governance exception or unexplained transfer.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 2,000 | $416.7188 | $833K |
| Sale | Common Stock | 2,000 | $417.8875 | $836K |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 4,000 | $411.0775 | $1.64M |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. This plan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $410.905 to $411.25. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $416.49 to $417.405. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $417.84 to $418.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate family members are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
